Correspondence 0001437749-23-001361 from AEMETIS, INC (AMTX) (CIK 0000738214) (AMTX)
AEMETIS, INC (AMTX) (CIK 0000738214)
Date: Jan. 19, 2023 · CIK: 0000738214 · Accession: 0001437749-23-001361
AI Filing Summary & Sentiment
File numbers found in text: 001-36475
Referenced dates: January 3, 2023
Letter
amtx20230118_corresp.htm
S H E A R M A N & S T E R L I N G L L P
1460 El Camino Real
Menlo Park, CA 94025
+1.650.838.3600
January 19, 2023
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Industrial Applications and Services
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jeanne Baker and Terrence O’Brien
Re: Aemetis, Inc.
Form 10-K for the Year Ended December 31, 2021
Filed March 10, 2022
Form 8-K filed November 3, 2022
File No. 001-36475
Ladies and Gentlemen:
On behalf of Aemetis, Inc. (the “Company”), we are submitting this letter in response to the written comment of the staff (the “Staff”) of the Securities and Exchange Commission (the “SEC”), as contained in your letter, dated January 3, 2023 (the “Comment Letter”), to the Company regarding the Company’s above-referenced Form 8-K filed November 3, 2022.
To facilitate your review of the Company’s response, we have repeated your comment in italics followed immediately by the response of the Company.
Form 8-K filed November 3, 2022
Exhibit 99.1, page 1
You indicate in your response to prior comment 2 that the cash receipt of a $14.2 million grant from the United States Department of Agriculture Biofuel Producer Program was not an adjustment in your reconciliation of net loss to Adjusted EBITDA because you use and communicate Adjusted EBITDA to investors as a proxy for the Company’s source or use of cash during the period. We have the following additional comments:
• Your disclosures indicate that you provide non-GAAP measures as a supplement to financial results based on GAAP. We also note that you reconcile Adjusted EBITDA to net income (loss). Please confirm that you will revise your disclosures to clarify why you present Adjusted EBITDA and reconcile this non-GAAP liquidity measure to the most comparable GAAP liquidity measure (e.g., cash flows from operating activities). Refer to Rule 10(e)(1)(i)(b) of Regulation S-K; and
• Please note that any non-GAAP performance measure that excludes the $14.2 million grant may not be in compliance with Question 100.03 of the non-GAAP C&DIs. In this regard, the fact that the grant was paid in cash does not sufficiently explain why it is not an appropriate adjustment to arrive at Adjusted EBITDA, as currently presented as a performance measure.
The Company respectfully acknowledges the Staff’s comments and confirms that it will (i) revise its disclosures in future earnings releases to clarify the use of Adjusted EBITDA by management as a non-GAAP liquidity measure to serve as a proxy for the Company’s source or use of cash during the period and (ii) reconcile such non-GAAP liquidity measure to the most comparable GAAP liquidity measure. The Company also acknowledges and confirms that, in accordance with Question 100.03 of the non-GAAP C&DIs, to the extent it presents a non-GAAP performance measure to investors in future earnings releases, it will exclude gains (such as certain grants paid in cash) in addition to charges from such non-GAAP performance measure.
*****
We thank the Staff for its consideration of the Company’s Form 8-K filed on November 3, 2022, and hope the Staff finds that the foregoing answer is responsive to its comment. If you should have any questions or further comments with respect to the Company’s Form 8-K, please do not hesitate to contact me at (650) 838-3720.
Yours very truly,
/s/ Yian Huang
Yian Huang
cc: Todd Waltz, Aemetis, Inc.
Chris Forrester, Shearman & Sterling LLP
SHEARMAN.COM
Shearman & Sterling LLP is a limited liability partnership organized in the United States under the laws of the state of Delaware, which laws limit the personal liability of partners.
Show Raw Text
CORRESP 1 filename1.htm amtx20230118_corresp.htm S H E A R M A N & S T E R L I N G L L P 1460 El Camino Real Menlo Park, CA 94025 +1.650.838.3600 January 19, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeanne Baker and Terrence O’Brien Re: Aemetis, Inc. Form 10-K for the Year Ended December 31, 2021 Filed March 10, 2022 Form 8-K filed November 3, 2022 File No. 001-36475 Ladies and Gentlemen: On behalf of Aemetis, Inc. (the “Company”), we are submitting this letter in response to the written comment of the staff (the “Staff”) of the Securities and Exchange Commission (the “SEC”), as contained in your letter, dated January 3, 2023 (the “Comment Letter”), to the Company regarding the Company’s above-referenced Form 8-K filed November 3, 2022. To facilitate your review of the Company’s response, we have repeated your comment in italics followed immediately by the response of the Company. Form 8-K filed November 3, 2022 Exhibit 99.1, page 1 You indicate in your response to prior comment 2 that the cash receipt of a $14.2 million grant from the United States Department of Agriculture Biofuel Producer Program was not an adjustment in your reconciliation of net loss to Adjusted EBITDA because you use and communicate Adjusted EBITDA to investors as a proxy for the Company’s source or use of cash during the period. We have the following additional comments: • Your disclosures indicate that you provide non-GAAP measures as a supplement to financial results based on GAAP. We also note that you reconcile Adjusted EBITDA to net income (loss). Please confirm that you will revise your disclosures to clarify why you present Adjusted EBITDA and reconcile this non-GAAP liquidity measure to the most comparable GAAP liquidity measure (e.g., cash flows from operating activities). Refer to Rule 10(e)(1)(i)(b) of Regulation S-K; and • Please note that any non-GAAP performance measure that excludes the $14.2 million grant may not be in compliance with Question 100.03 of the non-GAAP C&DIs. In this regard, the fact that the grant was paid in cash does not sufficiently explain why it is not an appropriate adjustment to arrive at Adjusted EBITDA, as currently presented as a performance measure. The Company respectfully acknowledges the Staff’s comments and confirms that it will (i) revise its disclosures in future earnings releases to clarify the use of Adjusted EBITDA by management as a non-GAAP liquidity measure to serve as a proxy for the Company’s source or use of cash during the period and (ii) reconcile such non-GAAP liquidity measure to the most comparable GAAP liquidity measure. The Company also acknowledges and confirms that, in accordance with Question 100.03 of the non-GAAP C&DIs, to the extent it presents a non-GAAP performance measure to investors in future earnings releases, it will exclude gains (such as certain grants paid in cash) in addition to charges from such non-GAAP performance measure. ***** We thank the Staff for its consideration of the Company’s Form 8-K filed on November 3, 2022, and hope the Staff finds that the foregoing answer is responsive to its comment. If you should have any questions or further comments with respect to the Company’s Form 8-K, please do not hesitate to contact me at (650) 838-3720. Yours very truly, /s/ Yian Huang Yian Huang cc: Todd Waltz, Aemetis, Inc. Chris Forrester, Shearman & Sterling LLP SHEARMAN.COM Shearman & Sterling LLP is a limited liability partnership organized in the United States under the laws of the state of Delaware, which laws limit the personal liability of partners.